Congenital toxoplasmosis affects between 1 and 10 in 10,000 newborn babies in Europe. Among them, 1% to 2% develop learning difficulties or die, and 4% to 27% develop ocular lesions leading to permanent impairment of vision in the affected eye. The main source of infection is by ingestion of viable tissue cysts in meat or oocysts excreted by cats. The exact mode of acquisition of infection is not clear, thus making it difficult to identify the risk factors. Prevention of congenital toxoplasmosis therefore depends on avoidance of infection during pregnancy.

Acute primary maternal toxoplasmosis if acquired during the first trimester of pregnancy can cause significant morbidity and mortality in developing fetuses. Congenital infection of the fetus in women infected just before conception is extremely rare; and even during the first few weeks of pregnancy, the maternal-fetal transmission rate is low. The risk of fetal infection rises from 6% at 13 weeks to 72% at 36 weeks. Fetuses acquiring infections between 24 and 30 weeks of gestation have been shown to carry the highest risk of suffering from long-term complications. The aim of prenatal serological screening for toxoplasmosis is to identify and treat maternal infection as soon as possible in order to prevent transmission of the parasite to the fetus. However, despite widespread provision of prenatal toxoplasma screening, the effectiveness of prenatal treatment is uncertain.

Various histological and serological techniques, such as the Sabin-Feldman dye test, direct hemagglutination test, enzyme-linked immunosorbent assay (ELISA), and indirect fluorescent antibody tests, are commonly applied to detect Toxoplasma gondii infection.
Screening for *T. gondii* infection.

For screening purposes, detection of antibodies against *T. gondii* is generally believed to be the most acceptable test. Different assays have been developed to detect anti-toxoplasma antibodies (immunoglobulin M [IgM], IgG, IgA, and IgE) in the sera of pregnant women with a history of repeated abortions and women suspected of being infected with *T. gondii.* The prolonged presence of specific IgM in the peripheral blood makes it difficult to differentiate acute from chronic infection. Detection of *Toxoplasma*-specific IgA and IgE antibodies in sera of pregnant women appears to be more sensitive than IgM detection during acute infection, but this is awaiting evaluation in a larger study.

Seroprevalence studies are useful means of gathering estimates of a population at risk and the number of infected individuals. Screening for *T. gondii* infection by detection of specific IgG and IgM in the antenatal care unit is routinely practiced at King Khalid University Hospital. This study examines the seroprevalence of *T. gondii* during pregnancy.

**Patients and Methods**

This was a retrospective analysis of laboratory data for *T. gondii* screening in the antenatal care unit at the King Khalid University Hospital in Riyadh. Between September 2009 and August 2010, sera from a total of 2176 pregnant women with mean (SD) age of 25 (7.3) years and mean duration of pregnancy of 18 (7.7) weeks were screened in the Immunology Division. Data were extracted for the presence or absence of anti-*T. gondii* IgG and IgM antibodies. Specific IgG antibodies against *T. gondii* were detected by indirect hemagglutination test (Wampole Laboratories, Princeton, NJ).

![Figure 1. Seroprevalence of Toxoplasma gondii: Assessment of specific IgG and IgM during pregnancy (n=2176).](image)

The test consists of stabilized sheep erythrocytes sensitized with *T. gondii* antigen, which reacts with the antibodies present in the serum. A titer of 1:64 and above indicates a positive test. Although variation in titer may occur, the assay has never been reported to yield a single false-positive or false-negative reaction. Anti-*T. gondii* IgM antibodies were assessed by ELISA (Vircell SL, Santa Fe, Granada, Spain). The assay is based upon the capture of IgM in the sample, with anti-IgM antibodies adsorbed on the polystyrene surface. When compared with other ELISA kits, this kit has been shown to have a sensitivity of 98% and specificity of 100% with virtually no cross-reactivity.

**Results**

The mean (SD) age of the pregnant females assessed was 25 (7.3) years, and duration of gestation was 18 (7.7) weeks at the time of screening for *T. gondii* infection. Figure 1 shows the seroprevalence of *T. gondii* in 2176 women screened during pregnancy. Of 2176 sera tested, 1351 (62%) did not show any evidence of exposure to *T. gondii*. The rest of the group, comprising 825 (38%) women, tested positive for anti-*T. gondii* IgG, and none was found to have anti-*T. gondii* IgM antibodies in the serum. These data reveal that a significantly high number of women in the antenatal care unit at King Khalid University Hospital in Riyadh had been exposed to *T. gondii*.

**Discussion**

The mortality and morbidity associated with congenital toxoplasmosis have prompted several studies involving serological screening for *T. gondii* infection during pregnancy. This study shows that, although none of the women screened during pregnancy had anti-*T. gondii* IgM, 38% tested positive for anti-*T. gondii* IgG, indicating exposure in the past. Similar findings have already been reported in a study from Turkey, in which none of the women during their pregnancy tested positive for anti-*T. gondii* IgM antibodies, and none was found to have anti-*T. gondii* IgM antibodies in the serum. These data reveal that a significantly high number of women in the antenatal care unit at King Khalid University Hospital in Riyadh had been exposed to *T. gondii*.
Seroprevalence of *T. gondii* assessed by the presence of specific IgG antibodies in this study (38%) when compared with the seroprevalence rate of 3.7% among pregnant Korean women appears to be alarmingly high. The lower rate of seroprevalence in Korean women, however, seems to be unique, as a number of other studies have reported seroprevalence rates between 20% and 43% among pregnant women in other parts of the world. Based on the IgG avidity test and polymerase chain reaction for detection of toxoplasma infection in pregnant women, a separate study from Kuwait has reported toxoplasma prevalence of 53.1%. These data suggest that *T. gondii* seroprevalence among pregnant women exhibits a trend of regional variation. The higher seroprevalence observed in the present study and the study from Kuwait may suggest a tendency towards a higher *T. gondii* seroprevalence in the Middle East.

Regional variation has been attributed to climate, cultural differences in the amount and type of raw meat consumed, and the increased consumption of meat from animals farmed indoors and frozen meat. A multicenter study has identified eating raw or undercooked lamb, beef, or other meat as the most important single risk factor for acquiring toxoplasma infection, apart from some association with travel outside Europe, United States, and Canada. There is sufficient evidence to believe that—compared with beef and chicken—lamb, goat or other meats are more commonly infected and may contain viable cysts. Undercooked lamb but not beef has been identified as a risk factor in Norway, whereas in northern France beef and lamb have been shown to be potent risk factors. Similarly, contact with soil has also been regarded as an independent risk factor for *T. gondii* seroconversion during pregnancy, while contact with cat litter may also pose a risk in certain situations. Identification of regional lifestyle risk factors for toxoplasmosis is of utmost importance for creating awareness for avoidance of toxoplasmosis in general and specifically during pregnancy.

Many pregnant women lack knowledge of the risk factors involved for the transmission of toxoplasmosis. Counseling of pregnant women about risk factor reduction may reduce the risk of congenital toxoplasmosis. The issue is further complicated by the observation that obstetricians, internists, and family practitioners lack relevant education of the risk factors for toxoplasmosis transmission. Studies focusing on education of pregnant women have proven to be effective in increasing general knowledge about toxoplasmosis and potentially decreasing the incidence of congenital toxoplasmosis.

This study describes the seroprevalence of *T. gondii* among pregnant women at a single tertiary care hospital, and the findings may not be applicable to the community on the whole. It is therefore recommended that a multicenter study investigating the seroprevalence of *T. gondii* across Saudi Arabia be conducted to assess the actual prevalence of *T. gondii* among pregnant women. In addition, attempts should be made for identification and avoidance of the local sources of infection.
REFERENCES

1. Gilbert RE. Epidemiology of infection in pregnant women. In: Petersen E, Amboise-Thomas F, editors. Congenital toxoplasmosis: Scientific background, clinical management and control. Paris: Springer-Verlag France; 1999.

2. Guerina NG, Hau HV, Meissner HC, Maguire JH, Lynfield R, Stenchenberg B, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1586-83.

3. Koppe JG, Loewer Sieger DH, de Roever Bonnet H. Results of 26-year follow-up of congenital toxoplasmosis. Lancet 1996;1:254-6.

4. Lappalainen M, Koskiemi M, Hiilesmaa V, Ammälä P, Teramo K, Koskela P, et al. Outcome of children after maternal primary Toxoplasma infection during pregnancy with emphasis on avidity of specific IgG. Pediatr Infect Dis J 1995;14:354-81.

5. Lebech M, Andersen D, Christensen NC, Heret J, Nielsen HE, Petersen B, et al. Feasibility of neonatal screening for toxoplasmosis infection in the absence of prenatal treatment. Lancet 1999;353:1834-7.

6. Remington JS, McLeod R, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn. 4th ed. Pennsylvania: WB Saunders; 1995. p. 140-267.

7. Hall SM, Congenital toxoplasmosis. BMJ 1992;305:291-7.

8. Newton LH, Hall SM. A survey of health education material for the primary prevention of congenital toxoplasmosis. Commun Dis Rep CDR Rev 1996;6:R2-7.

9. Thiebaut R, Leproust S, Chené G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients' data. SYRcot (Systematic Review on Effectiveness of prenatal treatment for congenital toxoplasmosis) Study Group. Lancet 2007;369:115-22.

10. Emna S, Karim A, Mohammed K, Aida B. Difficulty in dating primary infections by Toxoplasma gondii in pregnant women in Tunisia. Tunis Med 2006;84:95-7.

11. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: Risk estimates for clinical counseling. Lancet 1999;353:1629-33.

12. Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: Retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 2001;30:1303-8.

13. Sabin AB. Dyes as microchemical indicators of a new phenomenon affecting a protozoan parasite toxoplasma. Science 1940;108:680-3.

14. Deoments G, Remington JS. Direct agglutination test for diagnosis of Toxoplasma infection: Method for increasing sensitivity and specificity. J Clin Microbiol 1980;11:562-8.

15. Naot Y, Remington JS. An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: Use for diagnosis of acute acquired toxoplasmosis. J Infect Dis 1980;142:757-86.

16. Remington JS, McLeod R. Toxoplasmosis. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. Philadelphia: WB Saunders Company; 1992. p. 1328-43.

17. Pelloux H, Fricker-Hidalgo H, Goullier-Fleuret P, Ambroise-Thomas P. Detection of anti-toxoplasma immunoglobulin M in pregnant women. J Clin Microbiol 1997;35:2187.

18. Liesenfeld O, Press C, Montoya JG, Gill R, Isaacson-Renton JL, Hedman K, et al. False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: The Platea Tox IgM test. J Clin Microbiol 1997;35:174-7.

19. Turunen H, Vuorio KA, Leinikki PO. Determination of IgG, IgM and IgA antibody responses in human toxoplasmosis by enzyme-linked immunosorbent assay (ELISA). Scand J Infect Dis 1983;15:307-11.

20. Ashburn D, Joss AW, Penningth TN, Ho-Yen DO. Do IgA, IgG and IgD avidity tests have any value in the diagnosis of toxoplasma infection in pregnancy? J Clin Pathol 1996;49:312-5.

21. Nissapatorn V, Noor Azmi MA, Cho SM, Fong MY, Int I, Rohela M, et al. Toxoplasmosis: Prevalence and risk factors. J Obstet Gynaecol 2003;23:618-24.

22. Koskiemi M, Lappalainen M, Koskela P, Hedman K, Ammälä P, Hiilesmaa V, et al. The program for antenatal screening of toxoplasmosis in Finland: A prospective cohort study. Scand J Infect Dis Suppl 1992;49:70-4.

23. Lappalainen M, Koskela P, Hedman K, Teramo K, Ammälä P, Hiilesmaa V, et al. Incidence of primary toxoplasma infections during pregnancy in southern Finland: A prospective cohort study. Scand J Infect Dis 1999;24:97-104.

24. Morris A, Croxon M. Serological evidence of Toxoplasma gondii infection among pregnant women in Auckland, NZ. Med J 2004;117:U770.

25. Ertug S, Okyay P, Turkmen M, Yuksel H. Sero-prevalence and risk factors for toxoplasma infection among pregnant women in Aydin province, Turkey, BMC Public Health 2005;5:68.

26. Nowakowska D, Slaska M, Kostrzewska E, Wilczynski A, Jans T. gondii antibody concentration in sera of pregnant women in the sample of Lodz population. Wiad Parazytol 2001;47:83-9.

27. Han K, Shin DW, Lee TY, Lee YH. Seroprevalence of Toxoplasma gondii infection and risk factors associated with seropositivity of pregnant women in Korea. J Parasitol 2008;94:963-5.

28. Iqbal J, Khalid N. Detection of acute Toxoplasma gondii infection in early pregnancy by IgG avidity and PCR analysis J Med Microbiol. 2007;56:1495-9.

29. Decavallas G, Papapetropoulos M, Gianoulaki E, Tsitsounis V, Kondakos XG. Prevalence of Toxoplasma gondii antibodies in gravidas and recently aborted women and study of risk factors. Eur J Epidemiol 1999;6:223-8.

30. Dupuy J, Martin H, Gavinet MF, Paugam A, Tourte Schaeffer C. Transmission, incidence and prevalence of toxoplasmosis. Med Mal Infect 1993;23:139-47.

31. Gilbert RE, Tooney PA, Cubitt WD, Ades AE, Masters J, Peckham CS. Prevalence of toxoplasma IgA among pregnant women in west London according to country of birth and ethnic group. BMJ 1993;306:185-70.

32. Newton LH, Hall SM. A survey of health education material for the primary prevention of congenital toxoplasmosis. Commun Dis Rep CDR Rev 1996;6:R2-7.

33. Koppe JG, Loewer Sieger DH, de Roever Bonnet H. Results of 26-year follow-up of congenital toxoplasmosis. Lancet 1996;1:254-6.

34. Gilbert RE, Tooney PA, Cubitt WD, Ades AE, Masters J, Peckham CS. Prevalence of toxoplasma IgA among pregnant women in west London according to country of birth and ethnic group. BMJ 1993;306:185-70.

35. Cook AJ, Gilbert RE, Buffalino W, Zufferey R, Petersen E, Jenum PA, et al. Sources of toxoplasmosis infection in pregnant women: European multicentre case-control study. BMJ 2000;321:142-7.

36. Dubey JP. Strategies to reduce transmission of Toxoplasma gondii to animals and humans. Vet Parasitol 1996;64:85-70.

37. Dubey JP. Toxoplasmosis in sheep, goats, pigs and cattle. In: Dubey J, Beattie C, editors. Toxoplasmosis in animals and man. Boca Raton, Florida: CRC Press; 1988. p. 81-114.

38. Desmots G, Couvreur J, Alison F, Baudelot J, Gerbeaux J, Leong M. Epidemiological study on toxoplasmosis: The influence of cooking slaughtered animal meat on the incidence of human infection. Rev Fr Etud Clin Biol 1965;10:952-8.

39. Smith JL. Foodborne toxoplasmosis. J Food Safety 1991;12:7-57.

40. Kapperud G, Jenum PA, Stray Pedersen B, Melby KK, Eskild A, Eng J. Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Am J Epidemiol 1999;144:405-12.

41. Baril L, Ancelle T, Thulliez P, Goulet V, Tirard V, Carme B. Facteurs de risque d’aquisition de la toxoplasmose chez les femmes enceintes en 1995 (France): Bulletin Epidemiologique Hebdomadaire 1998;16:73-5.

42. Kravetz JD, Federman DG. Prevention of toxoplasmosis in pregnancy: Knowledge of risk factors. Infect Dis Obstet Gynecol 2000;13:161-5.

43. Pawlowski ZS, Gromadzka-Sutkiewicz M, Skommer J, Paul M, Rokossowski H, Suchocka E, et al. Impact of health education on knowledge and prevention behavior for congenital toxoplasmosis: The experience of Poznan, Poland, Health Educ Res 2001;16:400-502.

44. Foulon W, Naessens A, Ho-Yen D. Prevention of congenital toxoplasmosis. J Perinat Med 2000;28:337-45.